Free Trial
NASDAQ:NAMS

NewAmsterdam Pharma (NAMS) Stock Price, News & Analysis

NewAmsterdam Pharma logo
$25.31 +2.35 (+10.24%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$25.14 -0.16 (-0.65%)
As of 08/8/2025 06:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About NewAmsterdam Pharma Stock (NASDAQ:NAMS)

Key Stats

Today's Range
$23.23
$25.85
50-Day Range
$17.96
$25.31
52-Week Range
$14.06
$27.29
Volume
1.84 million shs
Average Volume
740,259 shs
Market Capitalization
$2.84 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.20
Consensus Rating
Moderate Buy

Company Overview

NewAmsterdam Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

NAMS MarketRank™: 

NewAmsterdam Pharma scored higher than 72% of companies evaluated by MarketBeat, and ranked 272nd out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    NewAmsterdam Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    NewAmsterdam Pharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about NewAmsterdam Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for NewAmsterdam Pharma are expected to decrease in the coming year, from ($1.75) to ($1.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NewAmsterdam Pharma is -15.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NewAmsterdam Pharma is -15.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    NewAmsterdam Pharma has a P/B Ratio of 3.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    11.06% of the float of NewAmsterdam Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    NewAmsterdam Pharma has a short interest ratio ("days to cover") of 8.4.
  • Change versus previous month

  • Dividend Yield

    NewAmsterdam Pharma does not currently pay a dividend.

  • Dividend Growth

    NewAmsterdam Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.06% of the float of NewAmsterdam Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    NewAmsterdam Pharma has a short interest ratio ("days to cover") of 8.4.
  • Change versus previous month

  • News Sentiment

    NewAmsterdam Pharma has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for NewAmsterdam Pharma this week, compared to 6 articles on an average week.
  • Search Interest

    1 people have searched for NAMS on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, NewAmsterdam Pharma insiders have sold 1,599.84% more of their company's stock than they have bought. Specifically, they have bought $236,839.00 in company stock and sold $4,025,887.00 in company stock.

  • Percentage Held by Insiders

    20.84% of the stock of NewAmsterdam Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    89.89% of the stock of NewAmsterdam Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about NewAmsterdam Pharma's insider trading history.
Receive NAMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter.

NAMS Stock News Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Up 10.1% on Analyst Upgrade
See More Headlines

NAMS Stock Analysis - Frequently Asked Questions

NewAmsterdam Pharma's stock was trading at $25.70 at the beginning of 2025. Since then, NAMS shares have decreased by 1.5% and is now trading at $25.31.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) posted its earnings results on Wednesday, August, 6th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.37. The business had revenue of $19.15 million for the quarter, compared to the consensus estimate of $1.44 million. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative trailing twelve-month return on equity of 27.27%.

Top institutional investors of NewAmsterdam Pharma include Jennison Associates LLC (2.62%), TimesSquare Capital Management LLC (0.78%), Aberdeen Group plc (0.65%) and Bank of New York Mellon Corp (0.31%). Insiders that own company stock include Nap BV Forgrowth, James N Topper, Michael H Davidson, Douglas F Kling, Louis G Lange, Louise Frederika Kooij, Juliette Berangere Audet and Johannes Jacob Piete Kastelein.
View institutional ownership trends
.

Shares of NAMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NewAmsterdam Pharma investors own include Nextera Energy Partners (NEP), Enterprise Products Partners (EPD), Blue Owl Capital (OBDC), Pimco Corporate & Income Opportunity Fund (PTY), PayPal (PYPL) and Ventyx Biosciences (VTYX).

Company Calendar

Last Earnings
8/06/2025
Today
8/10/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NAMS
CIK
1936258
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

High Price Target
$52.00
Low Price Target
$27.00
Potential Upside/Downside
+62.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.62)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$241.60 million
Net Margins
-259.07%
Pretax Margin
-258.91%
Return on Equity
-27.27%
Return on Assets
-25.00%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
21.08
Quick Ratio
19.98

Sales & Book Value

Annual Sales
$45.56 million
Price / Sales
62.37
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.93 per share
Price / Book
3.65

Miscellaneous

Outstanding Shares
112,270,000
Free Float
88,874,000
Market Cap
$2.84 billion
Optionable
Optionable
Beta
-0.02
10 Stocks Set to Soar in Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:NAMS) was last updated on 8/10/2025 by MarketBeat.com Staff
From Our Partners